What We Do

GenoME has developed an expedited innovative pipeline to deliver rapid, cost effective liquid biopsy tests. The pipeline can be utilised for biomarker development in a wide range of disease and applications, such as companion diagnostics for patient selection and stratification, disease monitoring, or early diagnosis in other disease areas.

Diagnostics have typically focused on mutations and protein changes. However, these changes are often only observed in a small subset of patient populations, or may lack sensitivity and specificity, particularly for early detection and liquid biopsy applications. We focus on DNA methylation; changes which are known to occur early in disease progression, and are highly conserved in liquid biopsies.

GenoME performs innovative biomarker discovery and evaluation. The end result is a highly accurate, simple and cost-effective PCR test with multiple biomarkers tested in one sample.